Clarus
Venture capitalCambridge
Fund manager profile
Clarus is a venture fund manager based in Cambridge. SEC filings show 4 venture funds on record, most recently Clarus IV-C, L.P. ($880M offering) filed May 2017.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 11 of 11 portfolio companiesBiotech ×10Healthtech ×3Medical Devices ×2AI & Machine Learning ×1Hardware ×1
HQs:United States×10
Investments · 11 tracked
founders shown can be your intro pathBy year:2018 · 22017 · 12016 · 62015 · 211 dated
BiotechLa Jolla, US
Eric W. Roberts(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Sudarshan Hebbar(Executive Officer)Michael J. Dunn(Executive Officer)
Board seatEmmett Cunningham· per SEC Form D · $80.4M raise · filed Jun 2018
Co-investorsSanderling VenturesOrbiMed
Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.
BiotechCambridge, US
Kiran Reddy(Executive Officer, Director)
Board seatNicholas GalakatosNicholas G. Galakatos· per SEC Form D · $10M raise · filed Jun 2019
Co-investorsOCV PartnersVida Ventures
Annexon Bio develops early complement inhibitors that target C1q, the initiating molecule of the classical complement pathway, to treat autoimmune, neurodegenerative, and ophthalmic diseases.
BiotechHealthtechSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)Thomas Wiggans(Director)Ricky Sun(Director)
Board seatEmmett Cunningham· per SEC Form D · $85M raise · filed Dec 2018
Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)
BiotechCambridge, US
Jill C. Milne(Executive Officer, Director)Ian Sanderson(Executive Officer)
BoardRon Laufer(Director)Jean George(Director)Michael Ross(Director)
Board seatNicholas Galakatos· per SEC Form D · $20.4M raise · filed Mar 2015
BiotechVancouver
Frank Perabo(Executive Officer)Franklin Berger(Director)Raymond Andersen(Executive Officer, Director)Scott Requadt(Director)Paul Cossum(Executive Officer)David Wood(Executive Officer)
Board seatScott Requadt· per SEC Form D · $15M raise · filed Jan 2016
Co-investorsOmega Funds
HealthtechMt Olive, US
Louis Altieri(Executive Officer)Larry Heaton(Executive Officer)
BoardSteven C. Adler(Director)David Jenkins(Director)Donald P. Carson(Director)
Board seatKurt Wheeler· per SEC Form D · $15M raise · filed Jun 2016
BiotechPlymouth, US
Brian Lawrence(Executive Officer, Director)Mark D Dacko(Executive Officer)Brian Levy(Director)William M Mower(Director)Alex Soltani(Director)
Board seatEmmett Jr. Cunningham· per SEC Form D · $11.2M raise · filed Oct 2017
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. KruseTimothy Springer(Director)Andrew Kruse(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)
Board seatScott Requadt· per SEC Form D · $25M raise · filed Aug 2016
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupPolaris PartnersSoleus Capital
BiotechCambridge, US
DAVID ANDERSON(CHIEF SCIENTIFIC OFFICER)JAMES MARTIN(CHIEF FINANCIAL OFFICER)CURT LOCKSHIN(CHIEF TECHNOLOGY OFFICER)JEFF BAXTER(CHIEF EXECUTIVE OFFICER AND PRESIDENT)Gary Robertson(Director)Carlos H. Fernandez-Mazzi(Director)
Board seatScott Requadt· per SEC Form D · $7M raise · filed Dec 2018
Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies.
BiotechHardwareHealthtechMedical DevicesToronto, US
Domenic Serafino(Executive Officer, Director)Kirk Gunhus(Executive Officer)Ross Portaro(Executive Officer)Anna Georgiadis(Executive Officer)Melissa Kang(Executive Officer)Michael Mandarello(Executive Officer)
Board seatEmmett CunninghamEmmett Cunningham, Jr.· per SEC Form D · $26M raise · filed Aug 2017
Co-investorsAPERTURE Venture PartnersEssex Woodlands Healthcare PartnersLongitude CapitalHealthQuest Capital
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsSV Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioCalcimedicaNASDAQ: CALCPraxis Precision MedicinesNASDAQ: PRAX
Portfolio news
latest coverage across their companiesPraxis Precision Medicines · investing.com · Aug 17, 2026
Venus Concept · stocktitan.net · Mar 18, 2026
Fund performance · per public LP disclosures · 2
as of Sep 2021| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Clarus Lifesciences II, L.P.LPs: California Public Employees' Retirement System | 2008 | — | 14.7% | 1.84x | 1.79x |
| Clarus Lifesciences I, L.P.LPs: California Public Employees' Retirement System, Michigan Municipal Employees' Retirement System | 2006 | — | 4.0% | 1.26x | 1.15x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- Where is Clarus located?
- Clarus is headquartered in Cambridge, US.